Gene-based continuous expression of FVIIa for the treatment of hemophilia.
Qualitative or quantitative defects in the genes for coagulation factors VIII (FVIII) or IX (FIX) result in a life-threatening, bleeding phenotype (hemophilia A (HA) or B (HB), respectively). Although hemophilia treatment by clotting factor replacement is effective, a proportion of patients develop neutralizing antibodies (inhibitors) to the infused factor that complicate the disease management. For inhibitor patients, recombinant human activated coagulation Factor VII (rhFVIIa), when administered at therapeutic doses, has been shown to bypass the deficiency in FVIII or FIX and result in hemostasis. As an alternative to this protein infusion therapy, a gene-based approach for the treatment of hemophilia with inhibitors has been developed, using continuous expression of a transgene coding for FVIIa following viral-mediated delivery. This approach was validated in hemophilic mice and, notably, in dogs as a model that closely resembles the human disease. In particular, liver-directed FVIIa gene delivery in hemophilic dogs resulted in multi-year transgene expression that ameliorated the bleeding phenotype, without thrombotic complications. These data support the gene-based FVIIa expression as a novel bypass therapy for hemophilia with inhibitors.
Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. margaritis@email.chop.edu
Paris
P
Margaritis
D000818:Animals; D005169:Factor VIII / Q000378:metabolism; D015942:Factor VIIa / Q000096:biosynthesis* / Q000235:genetics*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006467:Hemophilia A / Q000097:blood / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D006487:Hemostasis; D006801:Humans
D005169:Factor VIII; D015942:Factor VIIa